Heino Mary Anne

Director Heino Mary Anne sells 26,066 shares at blended avg $76.83; all 5 prior LNTH sales were well-timed at 90d mark.

Director Heino Mary Anne executed two separate sales totaling 26,066 shares for $2,002,570.47, reducing holdings by 7.6% from 344.7K to 318.6K shares. The timing warrants attention: all 5 of her prior trades at LNTH (dating to 2025-03-03) were well-timed at the 90-day mark, with the stock subsequently declining between -18.1% and -21.2% after each sale. Her cross-ticker track record shows a 47.37% well-timed sell rate across 19 prior open-market sells. The company's fundamentals remain solid (18.3% annual revenue growth, P/E of 21.64, $72.9M net income on $372.8M quarterly revenue), but the stock is down 35.6% from its 52-week high and down 26.2% over the past 30 days, suggesting the market is repricing the name regardless of operational strength. The pattern of repeated well-timed exits at this ticker deserves investor scrutiny.

Director Heino sells 53,107 LNTH shares across 5 transactions for $5,010,733.79 at blended $94.35, reducing stake 10.8%

Heino Mary Anne, a director, executed 5 separate sales totaling 53,107 shares for $5,010,733.79 on March 3, 2025, reducing her holdings by 10.8%. The sales occurred at prices ranging from $92.29 to $95.91, with a blended average of $94.35, while the current price is $100.48. Her prior sales at LNTH show a consistent pattern: 0 of 5 prior trades at this ticker were well-timed at the 90-day mark, with post-sale returns ranging from -0.6% to +11.8% over 30 days. The stock is currently up 12.2% over 30 days and 12.5% over 90 days, suggesting she sold below current market levels. With strong fundamentals including annual revenue growth of +18.3%, net income of $131,093,000.00, and a P/E of 16.64, the company shows operational health, though her sustained selling pattern across multiple tranches warrants observation of whether additional dispositions follow.

Director Mary Anne Heino sells 11,487 shares (11.5K) for $1.0M at blended avg $87.16; stock now down -24.1% in 30 days.

Director Mary Anne Heino executed 4 separate sales on 2024-11-08 totaling 11,487 shares for $1,001,217.84, reducing holdings by 2.5% to 443,436 shares. The transactions occurred at prices ranging from $86.32 to $89.58 per share, with a blended average of $87.16. Since the sale, the stock has declined significantly—down -24.1% over 30 days and -10.3% over 90 days—placing it -31.1% below its 52-week high of $123.62. At the same ticker (LNTH), Heino's 5 prior trades produced mixed timing outcomes: three August 2024 sales showed strong 30-day and 90-day gains (+10.1% to +11.8% at 30 days; +13.6% to +15.4% at 90 days), while two March 2024 sales were underwater at 30 days (-8.7% to -9.8%) before recovering at 90 days. Notably, 0 of 5 prior same-ticker sales proved well-timed by the 90-day standard, suggesting limited predictive power in her prior exits at this ticker. The company shows solid fundamentals—annual revenue growth of +38.6% and net income of $131.1M on $378.7M quarterly revenue—with a P/E of 13.85 and market cap of $5.9B, though the recent sharp equity depreciation and lack of prior well-timed exits at this ticker merit investor scrutiny.

Director Heino Mary Anne sold 10,481 shares at blended $95.50 for $1,000,899.61 on 2024-08-02; stock currently $98.15.

Heino Mary Anne executed 3 separate sales totaling 10,481 shares for $1,000,899.61 on 2024-08-02, reducing her holdings by 2.3% to 454,923 shares. The stock traded at a blended average of $95.50 during the sales and now stands at $98.15, a 2.8% price rise post-transaction. At LNTH specifically, 2 of her 5 prior sells exhibited negative 90-day returns (well-timed), while the most recent March 2024 sales showed post-sale declines of 8.7% to 10.6% in the 30-day window but later recovered to +23.6% to +26.3% by 90 days. The current environment shows the stock +24.4% over 30 days and +31.7% over 90 days, suggesting the market has rewarded LNTH holders significantly since her August sales. With fundamentals showing +38.6% annual revenue growth, $62.1M net income, and a 15.91 P/E ratio, this sale occurs in a period of strong stock appreciation, not during valuation distress.